GlassScriptPhysician profile
Tucker Coston
NPI 1295268803
$3,007.19
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $195 · 2021: $791 · 2022: $1,188 · 2023: $717 · 2024: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $564.56 | 2020-2022 | |
| Seagen INC. | $447.71 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $387.16 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $239.14 | 2022-2023 | Imfinzi |
| Janssen Biotech, INC. | $206.83 | 2022-2023 | Rybrevant |
| Rigel Pharmaceuticals, INC. | $175.58 | 2021-2022 | |
| Puma Biotechnology, INC. | $145.81 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $145.25 | 2023 | Somatuline Depot, Onivyde |
| Genentech USA, INC. | $140.25 | 2022 | |
| Glaxosmithkline, LLC. | $122.55 | 2022 | |
| Deciphera Pharmaceuticals INC. | $116.91 | 2024 | Qinlock |
| E.R. Squibb & Sons, L.L.C. | $116.05 | 2023 | Reblozyl |
| Legend Biotech USA INC. | $71.61 | 2023 | Carvykti |
| Alexion Pharmaceuticals, INC. | $71.39 | 2020-2023 | |
| Celgene Corporation | $25.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $17.02 | 2021 | |
| Abbvie INC. | $14.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tucker Coston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.